Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Abstract 3815: High-penetrance rare variants underlying familial lung cancer risk: Insights from the Genetic Epidemiology of Lung Cancer Consortium
Pikielny, Claudio W. , Xiao, Xiangjun , Peng, Bo , Li, Yafang , Tsavachidis, Spiridon, Gaba, Colette , Kupert, Elena, Goode, Ellen L., Crawford, Erin L. , Anderson, Marshall W., Cole, Michael D. , McKay, James , Field, John K. , Hung, Rayjean J., Mandal, Diptasri , Schwartz, Ann G. , Amos, Christopher I., Field, John K , Liu, Yanhong , Peng, Bo, Byun, Jinyoung , Cheng, Chao , Zhu, Dakai K. , Purrington, Kristen S. , Brennan, Paul E. , Liu, Geoffrey , Hung, Rayjean J., Christiani, David C. , Willey, James C. , Bailey‐Wilson, Joan E. , Pinney, Susan M.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 3815-3815

10.1158/1538-7445.am2025-3815 Get It

Background: Rare, functionally deleterious genetic variants have been implicated as having substantially larger effect sizes than common variants, potentially accounting for much of the missing heritability in lung cancer (LC). Over 25 years, the Genetic Epidemiology of LC Consortium (GELCC) has curated an invaluable resource of specimens and data from individuals with a strong family history of LC. Methods: Whole-genome and exome sequencing data were analyzed in 129 high-risk familial LC (FLC) families, defined as having two first-degree relatives or three or more second-degree relatives affected by LC (177 affected FLC and 309 unaffected relatives). The discovery focused on rare (allele frequency < 1% in gnomAD global population) and deleterious variations (missense, stop-gained, frameshift) enriched in FLC. Promising candidates were further external validated in 2,408 sporadic lung cancer (SLC) cases and 885 population controls from the International Lung Cancer Consortium. Results: We identified 168 variants with moderate-to-large effects on FLC risk, 100 of which were validated for SLC risk (Table 1 Table 1. Top 20 candidates Gene Rare (MAF < 1%), deleterious variants No. of variant carrier counts Odds Ratio, LC vs Control FLC | Relative | SLC | Control FLC+SLC SLC Oncogene ERBB3 / HER3 p.A1131T 3 | 1 | 2 | 0 35 15 JAK p.V651M 2 | 3 | 7 | 0 62 51 NOTCH3 p.R1560P 3 | 1 | 4 | 0 48 29 ROS1 p.N785X 6 | 4 | 10 | 0 110 74 USP6 p.R522 fs del 3 | 6 | 6 | 0 62 45 Tumor suppressor gene ATM p.L2332P 3 | 2 | 8 | 0 76 59 LZTS2 p.K458R 4 | 4 | 18 | 0 152 133 NPIPB13 p.V270 fs del 13 | 14 | 10 | 0 159 74 PARK2 / PRKN p.P153R 3 | 3 | 8 | 0 76 59 RB1 p.A525G 3 | 0 | 6 | 0 62 45 SLX4 p.S1716T 3 | 2 | 9 | 0 83 66 SYNE1 p.M6566I 2 | 0 | 7 | 0 62 52 TGFBRAP1 p.T301R 5 | 0 | 11 | 0 110 82 WNK1 p.K583 fs del 4 | 0 | 23 | 0 187 171 Other cancer-associated gene CFTR p.R74W 4 | 2 | 4 | 0 55 30 FLG p.R3404 fs del 7 | 2 | 4 | 0 69 30 LTN1 p.R349H 6 | 1 | 10 | 0 110 74 MLNR p.Q334 fs del 3 | 2 | 19 | 0 152 134 SLC39A11 p.R38Q 4 | 2 | 13 | 0 117 96 TTYH2 p.R493C 5 | 4 | 14 | 0 131 104 Dose effect of the top candidates No. candidates 0 variant allele 67 | 194 | 1911 | 834 reference reference 1 variant allele 50 | 66 | 363 | 50 3.5 (2.6 - 4.7) 3.2 (2.3 - 4.3) 2 variant alleles 15 | 18 | 62 | 1 32 (4.5 - 230) 27 (3.8 - 195) 3+ variant alleles 45 | 31 | 72 | 0 98 (6 - 1506) 62 (3.9 -1012) lists 20 top hits). Among these, 15 variants mapped to our previously identified lung cancer linkage locus at 6q23-25 (ROS1, PARK2, SYNE1). Others were enriched in oncogenes (ERBB3, JAK1, MET), tumor suppressor genes (ATM, BRCA2, RB1), and genes involved in the extracellular matrix (COL6A3, FLG, MUC5B). Importantly, individuals carrying more than two combinations of these variants exhibited exceptionally strong dose effects, with odds ratios (OR) exceeding 27. Conclusion: Our findings underscore the significant role of rare, high-penetrance variants in FLC etiology and highlight promising targets for early detection and personalized treatment. Future in-depth mechanistic studies are planned to evaluate the pathogenic effects of these specific alleles. Citation Format: Yanhong Liu, Claudio Pikielny, Xiangjun Xiao, Bo Peng, Yafang Li, Jinyoung Byun, Chao Cheng, Dakai Zhu, Spiridon Tsavachidis, Colette Gaba, Elena Kupert, Ellen L. Goode, Erin L. Crawford, Kristen Purrington, Marshall Anderson, Michael Cole, Paul Brennan, Geoffrey Liu, James McKay, John K. Field, Rayjean J. Hung, David C. Christiani, Diptasri Mandal, James C. Willey, Ann Schwartz, Joan Bailey-Wilson, Susan M. Pinney, Christopher I. Amos. High-penetrance rare variants underlying familial lung cancer risk: Insights from the Genetic Epidemiology of Lung Cancer Consortium [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3815.
Abstract 1682: Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E)
Mohiuddin, Md , Póvoa, Vanda , Fior, Rita , Sinicrope, Frank A. , Mohiuddin, Md

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 1682-1682

10.1158/1538-7445.am2025-1682 Get It

Abstract Background: Mutant BRAF(V600E) is present in 8-12% of human colorectal cancers (CRCs) and is associated with treatment resistance and poor survival. Targeted therapy with inhibitors of BRAF and EGFR is associated with only an incremental survival benefit. Methods: We studied the novel CDK2/CDK9 inhibitor, fadraciclib, alone and in combination with the BRAF inhibitor encorafenib on isogenic CRC cells with two, one, or no BRAFV600E alleles (RKO+/+, A19+/-, T29-/-). Analysis of apoptosis, colony formation, and the cell cycle was performed. The effect of drug treatment on growth of tumor xenografts was determined in a zebrafish model. Results: Fadraciclib induced apoptosis and inhibited colony formation in a gene dose-dependent manner. Its growth inhibitory effect when combined with encorafenib was synergistic. Mechanistically, fadraciclib suppressed the expression of pro-survival MCL-1 and decreased the phosphorylation of RNA polymerase II indicating suppression of RNA transcription. Fadraciclib also impaired Rb phosphorylation and promoted a DNA damage response indicated by the cleavage of PARP, pH2AX (ser139), and activation of p53. Drug treatment was associated with a greater suppression of Rb phosphorylation, cell cycle inhibition, and apoptosis in RKO+/+ versus A19+/- and T29-/- cells. In a zebrafish tumor xenograft model, fadraciclib plus encorafenib significantly reduced the tumor xenograft size concurrent with increased caspase-3 activation. Conclusion: Fadraciclib plus encorafenib potently induced apoptosis and synergistically suppressed tumor cell growth in a gene dose-dependent manner in BRAFV600E CRC cells, and exerted anti-tumor effects in a tumor xenograft model. These data suggest a novel therapeutic strategy in this CRC subtype. Citation Format: Md Mohiuddin, Vanda Póvoa, Rita Fior, Frank A. Sinicrope. Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E). [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1682.
Abstract 2698: Altered collagen morphology in pancreatic cancer treated with the iRGD tumor-penetrating peptide
Choi, Yoon Ho , Kim, Minji , Kawai, Hotaka , Kuroda, Yukihito , Chung, Seock‐Jin , Sugahara, Kazuki N. , Hwang, Tae Hyun , Miyamura, Norio

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2698-2698

10.1158/1538-7445.am2025-2698 Get It

Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense, collagen-rich stroma that impedes drug delivery. We investigated how iRGD-mediated nanoparticle delivery modifies collagen architecture using humanized mouse models. Computational analysis of Picro-Sirius Red-stained whole-slide images (WSIs) using curvelet transform-based fiber extraction method (CT-FIRE) was performed to quantitatively examine changes in collagen features, thereby understanding treatment-induced alterations in the tumor microenvironment (TME). Methods: Humanized PDAC mice were prepared with either the human PANC-1 cell line or 0779 primary human PDAC cells and treated with or without iRGD monotherapy for two months (n=12). Primary tumors were sectioned and stained with Picro-Sirius Red to visualize collagen structures. WSIs of Picro-Sirius Red-stained tissues were analyzed with CT-FIRE to extract six morphological features of collagen, including average fiber length, waviness, and density to capture structural changes. WSIs were divided into 256×256 pixel tiles with consistent sampling through bootstrapping, followed by permutation testing for statistical validation (1,000 permutations, p<0.01). Results: Computational analysis revealed significant iRGD-induced collagen remodeling with quantifiable changes in key structural and morphological features. Permutation testing showed that, compared to controls, average fiber length decreased by 3.27% (p<0.01), waviness reduced by 3.25% (p<0.01), and density diminished by 36.3% (p<0.01), compared to controls. The structural changes were more notable in 0779-derived tumors compared to PANC-1, with reductions in average fiber length (1.03%, p<0.01), waviness (8.78%, p<0.01), and collagen density (24.27%, p<0.01), demonstrating cell-line dependent stromal remodeling. Conclusions: Our findings suggest that long-term iRGD therapy alters collagen morphology in PDAC. Further investigation is warranted to understand how these alterations contribute to enhanced penetration of drugs and immune cells observed in iRGD-treated PDAC tumors. The observed cell-line dependent variations in stromal remodeling suggest tumor heterogeneity influences treatment response, highlighting the potential for personalized therapeutic approaches in stromal-rich tumors like PDAC. Citation Format: Yoon Ho Choi, Minji Kim, Hotaka Kawai, Yukihito Kuroda, Norio Miyamura, Seock-Jin Chung, Kazuki N. Sugahara, Tae Hyun Hwang. Altered collagen morphology in pancreatic cancer treated with the iRGD tumor-penetrating peptide [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2698.
Abstract 2701: iRGD peptide therapy transforms immunosuppressive microenvironment to immune-favorable state in pancreatic ductal adenocarcinoma
Kim, Minji , Choi, Yoon Ho , Kawai, Hotaka , Kuroda, Yukihito , Sugahara, Kazuki N. , Hwang, Tae Hyun , Miyamura, Norio

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2701-2701

10.1158/1538-7445.am2025-2701 Get It

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) exhibits a complex, immunosuppressive tumor immune microenvironment (TIME), necessitating molecular-level understanding to identify therapeutic targets. We investigated how iRGD peptide therapy remodels the immunosuppressive TIME to an immune-favorable state using single-cell spatial molecular analysis. Methods: Single-cell level in situ molecular imaging was performed using Xenium analyzer with 5K gene panel on tumor samples from humanized PDAC mice (n=7) treated with iRGD monotherapy (n=3) or control (n=4), enabling comprehensive spatial molecular characterization of the TIME. Results: iRGD therapy significantly transformed the immunosuppressive TIME to an immune-favorable state through T-cell composition remodeling. We observed increased populations of CD4+ memory T cells, CD4+ helper T cells, and cytokine-secreting effector T cells, indicating enhanced immune memory and effector functions. Concurrent decreases in regulatory T cells and activated CD4+ T cells reflected reduced immune suppression. Additionally, decreased TGF-β signaling in the iRGD cohort suggested TGF-β antagonism as a mechanism for overcoming immunosuppression. Conclusions: iRGD therapy effectively converted the immunosuppressive PDAC microenvironment to an immune-favorable state by enhancing beneficial T cell populations and reducing immunosuppression through TGF-β pathway modulation. These findings support previous work by Kuroda et al. and provide mechanistic rationale for the ongoing iRGD-based immunotherapy clinical trial (iLSTA:ACTRN12623000223639).Acknowledgments: We thank DeepL for the English language editing. Citation Format: Minji Kim, Yoon Ho Choi, Hotaka Kawai, Yukihito Kuroda, Norio Miyamura, Kazuki N. Sugahara, Tae Hyun Hwang. iRGD peptide therapy transforms immunosuppressive microenvironment to immune-favorable state in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2701.
Abstract 1946: Postoperative lymphatic exudate in HPV-negative head and neck cancer detects recurrence prior to adjuvant treatment decisions
Lazare, Seka , Harmon, Adam, Long, Megan , Tellis, Ashley , Whitfield, Damion , Khalil, Lucien , Francis, Marra S. , Chaudhuri, Aadel A. , Zevallos, José P. , Winckler, Wendy , Gu, Zhuosheng , Earland, Noah , Pacula, Maciej , Benson, Adam , Ferris, Robert L.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 1946-1946

10.1158/1538-7445.am2025-1946 Get It

Abstract Recurrence after surgery remains a major cause of failure in head and neck squamous cell carcinoma (HNSCC), particularly for HPV-negative patients whose 2-year failure rate is > 50%. There is unmet need for an accurate diagnostic test that predicts risk of recurrence prior to adjuvant therapy selection. We evaluated ctDNA in lymphatic exudate (“lymph”) collected via surgical drains at 24 hours to detect molecular residual disease (MRD) and compared its performance to plasma and adverse pathology features. Lymph, plasma and blood were collected from 76 HPV- HNSCC patients 24 hours after surgery. Tumor tissue was collected at surgery. 73 patients passed QC. Samples were sequenced using a 699-gene custom panel to a median of 6322x (lymph and plasma cfDNA) or 533x (tumor and blood genomic DNA). Tumor variants were directly genotyped in lymph and plasma using a tumor-informed pipeline. MRD status was determined using a calibrated cutoff based on mean variant allele fraction. Wilcoxon signed-rank test was used for comparisons. Kaplan-Meier estimator with log-rank test and Cox proportional hazards model were used for survival analysis. We previously demonstrated that 24 hour postoperative lymph ctDNA detects recurrence in HPV(-) HNSCC across two independent multi-site cohorts and by orthogonal sequencing approaches (sensitivity (SN) = 72%, specificity (SP) = 65%, p = 0.003, hazard ratio (HR) = 3.1, n = 73). When compared to other data available at this early time point (pathology and 24 hour postoperative plasma), lymph ctDNA outperformed each for recurrence detection (extranodal extension (ENE, p = 0.30), lymphovascular invasion (p = 0.02), perineural invasion (p = 0.38), positive lymph nodes (p = 0.03), plasma (p = 0.8)). We next evaluated lymph ctDNA in a critical subpopulation: patients considered intermediate risk by pathology (negative for ENE or margins but with one or more other adverse pathologic feature). Current NCCN guidelines recommend radiotherapy and to “consider systemic therapy” for these patients. Lymph ctDNA accurately stratified recurrence in this group with high sensitivity (SN = 88%, SP = 69%; P = 0.013, HR = 9.1, n = 24). Within this cohort, 77% of patients who received RT alone and later recurred were positive for lymph ctDNA at 24 hours, suggesting an opportunity to use molecular data in concert with pathology to identify patients who may benefit from adjuvant treatment intensification. Postoperative lymph represents a novel proximal analyte for MRD detection in HPV- HNSCC designed specifically for use in the immediate post-surgical window when adjuvant therapy decisions must be made. Lymph ctDNA is significantly associated with recurrence and outperforms both time-matched plasma and pathology. Accurate MRD identification at this early timepoint has the potential to augment traditional pathology and personalize adjuvant treatment paradigms in HPV-negative HNSCC. Citation Format: Seka Lazare, Zhuosheng Gu, Noah Earland, Adam Harmon, Maciej Pacula, Megan Long, Ashley Tellis, Damion Whitfield, Adam Benson, Lucien Khalil, Robert L. Ferris, Marra Francis, Aadel A. Chaudhuri, Jose P. Zevallos, Wendy Winckler. Postoperative lymphatic exudate in HPV-negative head and neck cancer detects recurrence prior to adjuvant treatment decisions [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1946.
Abstract 2800: Unraveling long non-coding RNA dynamics in uveal melanoma: Insights into pathogenesis, biomarkers, and targeted therapies
Gerolimos, Nikitas , Edralin, Sabrina , Xu, Clark , Simasiku, Akebu, Priniotakis, Georgios , Yue, Zongliang , Alevizos, Vasileios , Papakostas, George A. , Georlimos, Nikitas , Yue, Zongliang , Edralin, Sabrina , Xu, Clark

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2800-2800

10.1158/1538-7445.am2025-2800 Get It

Abstract Uveal melanoma (UM), a rare yet aggressive intraocular cancer with an estimated 5 cases per million people annually, presents a high metastatic risk and poor prognosis, highlighting an immeasurable need for novel diagnostic and therapeutic strategies. Not only is UM characterized by complex genetic and epigenetic aberrations, but it is also prone to deregulation of non-coding RNAs that could be used as therapeutic targets of diagnostic markers. In this study, we analyzed whole exome sequencing data from tumor and control samples of patients diagnosed with both uveal and cutaneous melanoma, focusing on a patient with a germline mutation in MBD4. Our framework, made up to work with long non-coding RNAs (lncRNAs), aims to flesh out these molecules' novel roles in disease etiology and progression. We identified several lncRNAs significantly associated with UM progression and computationally validated them in conjunction with microenvironmental factors in existing literature. LncRNAs are instructive in maintaining cellular homeostasis and, when deregulated, contribute to oncogenesis. Our results implied that the interaction between lncRNAs and other non-coding RNAs might be one of the most relevant mechanisms influencing UM pathogenesis. More interestingly, microenvironmental factors and lncRNA interplay are crucial in disease progression. The clinical relevance of our findings was tested using radiation treatment to evaluate potential therapeutic implications. Over and above that, we assessed the potential of lncRNAs as biomarkers and therapeutic targets in personalized medicine for UM patients to address ineffective treatments. The new lncRNA panels could serve as a new avenue for targeted therapy. With an in-depth understanding of the descent of molecular alterations and how lncRNAs interact within the tumor microenvironment, we can better size up potential strategies to cast off the challenges UM poses. Our work provides instructive insights into lncRNAs underpinnings of UM, emphasizing the significance of lncRNAs in tumor biology and their interactions within the microenvironment. We believe our findings will lay the groundwork for future therapeutic strategies and underscore the necessity for continued research to unravel the complex mechanisms in UM pathogenesis. Citation Format: Vasileios Alevizos, Nikitas Gerolimos, Sabrina Edralin, Clark Xu, Akebu Simasiku, Georgios Priniotakis, George A. Papakostas, Zongliang Yue. Unraveling long non-coding RNA dynamics in uveal melanoma: Insights into pathogenesis, biomarkers, and targeted therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2800.
Abstract 3583: The Breast Cancer Risk Prediction Project: a resource of 1.8 million women with diverse backgrounds from 20 prospective cohorts to improve breast cancer risk prediction and advance breast cancer epidemiology
Kraft, Peter, O’Meara, Ellen S. , Rohan, Thomas, Neuhouser, Marian L, Vachon, Celine M, Haiman, Christopher, White, Emily , Lee, I‐Min , Gaudet, Mia M. , Chatterjee, Nilanjan , Freeman, Laura E. Beane , Palmer, Julie R. , Genkinger, Jeanine M. , Lacey, James V. , Teras, Lauren R. , Visvanathan, Kala , Milne, Roger L. , Chen, Yu , Eliassen, A. Heather , Kitahara, Cari M. , O’Brien, Katie M. , Anderson, Garnet L. , Campbell, Archie I , Fortner, Renée T. , Lagerros, Ylva Trolle , Sandin, Sven , García‐Closas, Montserrat

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 3583-3583

10.1158/1538-7445.am2025-3583 Get It

Abstract Breast cancer risk assessment tools are widely used in clinical practice to guide decisions regarding screening timing and modality, lifestyle interventions, genetic testing, preventive therapy, and risk-reducing surgery. Although a number of tools designed for the general population are used in practice, they face a series of challenges including: (i) modest discriminatory ability due to lack of a unified model that flexibly incorporates a comprehensive set of risk factors; (ii) inability to produce subtype-specific risk estimates, relevant for tailoring screening and/or preventive strategies (e.g. prophylactic endocrine therapy that is effective only for hormone receptor positive tumors); (iii) lack of data from diverse populations to build models that work well for all women; and, (iv) scarcity of opportunities for comparative validation of different models. The Breast Cancer Risk Prediction Project (BCRPP), a collaboration currently including 20 prospective cohorts from the National Cancer Institute’s Cohort Consortium, is addressing these challenges by harmonizing, sharing, and analyzing data on over 1.8 million women, over 115, 000 of whom have developed breast cancer. The BCRPP is developing a comprehensive tool that will predict breast cancer risk, overall and by subtypes, across major racial and ethnic groups in the United States. This tool incorporates known and emerging risk factors (e.g. reproductive history, anthropometry, smoking, alcohol intake, medication use, mammography, family history, and measured genotypes). In parallel to model building and validation efforts, BCRPP investigators are developing privacy-preserving web and mobile interfaces to deliver the risk tools to patients and clinicians. Here we present descriptive data on participating cohorts (e.g. dates of enrollment, ages at enrollment, length of follow up, numbers of cases by subtype), summarize missing data patterns and our approach to model development and validation that accounts for heterogeneity in missingness patterns across cohorts, and describe data governance procedures and data sharing infrastructure (including pooled and federated analyses, to account for policy limitations on sharing individual data). Descriptive information and procedures for requesting and accessing data are available via the BCRPP data platform (https://epidataplatforms.cancer.gov/bcrpp/). Although originally assembled for risk model development, these data on a large and diverse sample of women with extensive harmonized risk factors and covariates can be a resource to address other outstanding questions in breast cancer epidemiology across time, the lifecourse, and diverse populations. Citation Format: Peter Kraft, Laura Beane-Freeman, Julie Palmer, Ellen O'Meara, Jeanine Genkinger, James Lacey, Thomas Rohan, Lauren Teras, Marian L. Neuhouser, Kala Visvanathan, Celine Vachon, Roger Milne, Christopher Haiman, Yu Chen, Heather Eliassen, Cari Kitahara, Katie O'Brien, Emily White, Garnet Anderson, I-Min Lee, Archie Campbell, Renee Fortner, Ylva Lagerros, Sven Sandin, Mia Gaudet, Montserrat Garcia-Closas, Nilanjan Chatterjee. The Breast Cancer Risk Prediction Project: a resource of 1.8 million women with diverse backgrounds from 20 prospective cohorts to improve breast cancer risk prediction and advance breast cancer epidemiology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3583.
Abstract 153: High-resolution profiling of the tumor microenvironment with spatial ecotypes
Brown, Erin L. , Jeon, Hyun Soo , Semenkovich, Nicholas P. , Schwab, Janella C. , Sachs, Chloe M., Gungoren, Bilge , Qaium, Faridi , Mudd, Jacqueline L. , Cai, Qingyuan , Bacchiocchi, Antonella , Halaban, Ruth , Chaudhuri, Aadel A., Semenkovich, Nicholas P , Zhang, Wubing , Usmani, Abul , Earland, Noah , Alahi, Irfan , Steen, Chloé Beate , Harris, Peter K , Fields, Ryan C. , Sznol, Mario , Chen, David Y. , Chaudhuri, Aadel A. , Newman, Aaron M.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 153-153

10.1158/1538-7445.am2025-153 Get It

Background: Multicellular programs in the tumor microenvironment (TME) drive cancer pathogenesis and response to therapy but remain challenging to identify and profile clinically. Here, we present Spatial EcoTyper, a multimodal machine learning framework for large-scale profiling of spatially dependent cell states and multicellular ecosystems, termed spatial ecotypes (SEs). Methods and Findings: By integrating five million single-cell and spot-level spatial transcriptomes from 10 diverse human neoplasms, including carcinomas and melanomas, we identified a rich tapestry of conserved regional plasticity across nine TME cell types. We then applied Spatial EcoTyper to deeply dissect these data, revealing nine novel SEs with broad conservation - each with unique biology, TME cell states, geospatial features, and clinical outcome associations. SEs were linked to specific biogeographic domains, including the tumor core, margin, and adjacent stroma, and were remarkably well-validated in 235 held-out tumor samples profiled by either single-cell RNA sequencing, sequencing-based spatial transcriptomics (10x Visium), or high-resolution imaging-based spatial transcriptomics (Vizgen MERSCOPE and NanoString CosMx). By deconvolving SEs from over 1,200 bulk tumor RNA-seq profiles, we discovered striking associations between SE levels and response to immune checkpoint inhibitors (ICIs), outperforming nearly 40 potential correlates of ICI response, including previously described signatures of tertiary lymphoid structures and tumor tissue PD-L1 expression. Notably, baseline levels of a proinflammatory SE - localized to the tumor core and defined by a hub of unique T cell, macrophage, fibroblast, and endothelial cell states - strongly forecasted ICI benefit, while another SE - localized to the tumor margin and defined by myofibroblast and hypoxia-associated endothelial cell states - portended ICI resistance. Conclusion: Our data reveal fundamental units of TME organization and demonstrate a platform for large-scale profiling of spatial cellular ecosystems in any tissue, with implications for improved forecasting of immunotherapy response and the development of novel therapeutic strategies. Citation Format: Wubing Zhang,Erin L. Brown,Abul Usmani,Noah Earland,Hyun Soo Jeon,Irfan Alahi,Nicholas P. Semenkovich,Janella C. Schwab,Chloé B. Steen,Chloe M. Sachs,Bilge Gungoren,Faridi Qaium,Peter K. Harris,Jacqueline Mudd,Qingyuan Cai,Antonella Bacchiocchi,Ryan C. Fields,Mario Sznol,Ruth Halaban,David Y. Chen,Aadel A. Chaudhuri,Aaron M. Newman. High-resolution profiling of the tumor microenvironment with spatial ecotypes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 153.
Abstract 2077: Elevated PI16 expression in fibroadenoma fibroblasts is associated with subsequent breast cancer development
Westerman, Pria, Cruz-Reyes, Nicole , Erak, Camila Pacheco, McCauley, Bryan M. , Sherman, Mark E. , Westerman, Pria, Vierkant, Robert A. , Winham, Stacey J. , Degnim, Amy C. , Radisky, Derek C.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2077-2077

10.1158/1538-7445.am2025-2077 Get It

Abstract Introduction: Fibroadenoma is the most common type of benign breast lesion and is not traditionally considered an indicator of increased breast cancer risk. This study aimed to identify biomarkers within fibroadenoma associated with subsequent breast cancer development using patient samples from the Mayo Clinic Benign Breast Disease (BBD) cohort. Methods: We analyzed formalin-fixed paraffin-embedded (FFPE) breast biopsy samples from patients diagnosed with non-proliferative fibroadenoma who either developed breast cancer later (n=10) or remained cancer-free (n=5). NanoString RNA profiling identified differentially expressed genes in fibroblasts associated with subsequent cancer development. Immunohistochemistry was first done to compare overall expression of PI16 in this cohort. Opal multiplex immunofluorescence staining (mIF) was then performed to evaluate the expression of PI16 in fibroblasts (Vim+PanCK-) and assess immune cell infiltration (CD45+) in different tissue compartments. Fibroblasts were identified by vimentin positivity (Vim+), and epithelial cells were marked by pan-cytokeratin positivity (PanCK+). Results: Compared to patients who remained cancer-free, those who developed breast cancer showed significantly increased expression of PI16 in fibroblasts (PI16+Vim+PanCK-, 3.25-fold increase, p=0.0011). Additionally, the number of immune cells (CD45+) was significantly decreased (0.52-fold, p=0.03) in the fibroadenoma lesions of patients who later developed cancer. Conclusions: Our findings suggest that elevated expression of PI16 in fibroblasts within fibroadenoma may serve as potential biomarkers for predicting breast cancer risk for women with fibroadenoma. PI16 encodes Peptidase Inhibitor 16, which is implicated in modulating fibroblast activity and extracellular matrix remodeling—processes that can contribute to a tumor-supportive microenvironment. Elevated levels of this protein in fibroblasts suggest an altered microenvironment that may foster tumor initiation and progression. The decreased immune cell infiltration further implies an immunosuppressive microenvironment that may facilitate cancer progression. As these markers can be detected in FFPE samples, our results could lead to the development of a readily applicable clinical test to identify fibroadenoma patients at increased risk for breast cancer, enabling earlier intervention and surveillance. Citation Format: Pria Westerman, Nicole Cruz-Reyes, Camila Pacheco Erak, Robert Vierkant, Bryan McCauley, Stacey Winham, Mark Sherman, Amy Degnim, Derek Radisky. Elevated PI16 expression in fibroadenoma fibroblasts is associated with subsequent breast cancer development. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2077.
Abstract 2741: Novel murine models of epigenetic dysregulation in SWI/SNF-mutated cholangiocarcinoma
Millender, Jayla T. , Watkins, Ryan , Carlson, Danielle M. , Werneburg, Nathan W., Tomlinson, Jennifer L. , Carlson, Danielle Marie , Sample, Jack W. , Smoot, Rory L. , Robertson, Keith D. , Gores, Gregory J. , Conboy, Caitlin B.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2741-2741

10.1158/1538-7445.am2025-2741 Get It

Abstract SWI/SNF chromatin remodeling complexes are frequently mutated across human cancers, including cholangiocarcinoma (CCA). Dysregulation of this complex due to loss of function mutations in AT-rich interaction domain-1A (ARID1A) and polybromo-1 (PBRM1) occur in up to 18% and 10% of cases respectively. SWI/SNF subunit mutations frequently co-occur alongside PI3K/AKT pathway activation. Preexisting literature suggests altered gene expression and protein synthesis contribute to CCA oncogenesis, but our understanding of these mechanisms remains immature. Genetically accurate preclinical models are needed to define the roles of ARID1A and PBRM1 in CCA and identify therapeutic targets. We developed novel murine models of CCA with either ARID1A, PBRM1 or dual ARID1A/PBRM1 (APAC) knockout in the context of AKT activation, utilizing a surgical biliary transfection method for somatic gene editing with CRISPR/Cas9. Within 8 months, mice formed numerous liver tumors, predominantly CCA and mixed CCA/HCC. Knockout of ARID1A and PBRM1 was confirmed through genomic PCR, qRT-PCR, and immunoblot assays. Histologically, murine APAC tumors displayed phenotypic similarities to human CCA, including dense cancer-associated fibroblast infiltration and variable CD45+ immune cell infiltration. A novel, syngeneic CCA cell line was isolated from a dual ARID1A/PBRM1 knockout tumor (APAC-2). RNA-sequencing of primary tumors and the APAC-2 cell line versus a non-invasive cholangiocyte cell line with AKT activation only (AC), was performed to identify differentially expressed genes (DEGs) of interest in ARID1A and PBRM1-deficient CCA. Periostin (Postn) was among the top upregulated genes in the APAC-2 cell line. POSTN is a secreted glycoprotein that is upregulated in human CCA and may be therapeutically targetable. Knockdown of periostin inhibited the in vitro growth of APAC-2 cells and a human CCA cell line with ARID1A mutation and periostin overexpression (HuH-28). These studies serve to characterize and validate a genetically relevant murine model of epigenetic dysregulation in ARID1A and PBRM1-deficient CCA. This model can be used for identification and validation of potential drug targets. Ongoing work focuses on studying multiple dysregulated pathways and testing dependence on genes of interest, including periostin, as potential treatment strategies for CCA. Citation Format: Jayla Millender, Jennifer Tomlinson, Ryan Watkins, Danielle Carlson, Jack Sample, Nathan Werneburg, Rory Smoot, Keith Robertson, Gregory Gores, Caitlin Conboy. Novel murine models of epigenetic dysregulation in SWI/SNF-mutated cholangiocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2741.